L-759,633

L-759,633
(IUPAC) ime
	(6aR,10aR)-1-metoksi-6,6,9-trimetil-3-(2-metiloktan-2-il)-6a,7,10,10a-tetrahidrobenzo[c]hromen
Klinički podaci
Identifikatori
CAS broj	.
ATC kod	nije dodeljen
PubChem	5311215
Hemijski podaci
Formula	C26H40O2
Mol. masa	384,593 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C26H40O2/c1-8-9-10-11-14-25(3,4)19-16-22(27-7)24-20-15-18(2)12-13-21(20)26(5,6)28-23(24)17-19/h12,16-17,20-21H,8-11,13-15H2,1-7H3 ; Key: SUFMHSFGODDLKI-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

L-759,633 je analgetički lek koji je kanabinoidni agonist. On je u znatnoj meri selektivan agonist za CB₂ receptor, sa selektivnošću od 163 puta za CB₂ u odnosu na CB₁.^[3]

On proizvodi slične efekte sa drugim kanabinoidnim agonistima poput analgezije, ali ima malo i je bez sedativnih ili psihoaktivnih efekata usled njegove slabe CB₁ aktivnosti. On ima relativno jako antiinflamatorno dejstvo usled jake CB₂ aktivnosti.^[4]^[5]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999). „Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630”. British Journal of Pharmacology 126 (3): 665–72. DOI:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.
↑ Huffman JW (2000). „The search for selective ligands for the CB2 receptor”. Current pharmaceutical design 6 (13): 1323–37. DOI:10.2174/1381612003399347. PMID 10903395.
↑ Huffman JW (2005). „CB2 receptor ligands”. Mini reviews in medicinal chemistry 5 (7): 641–9. DOI:10.2174/1389557054368844. PMID 16026310.

Povezano

Vanjske veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, Pertwee RG (1999). „Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630”. British Journal of Pharmacology 126 (3): 665–72. DOI:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.

[4] Huffman JW (2000). „The search for selective ligands for the CB2 receptor”. Current pharmaceutical design 6 (13): 1323–37. DOI:10.2174/1381612003399347. PMID 10903395.

[5] Huffman JW (2005). „CB2 receptor ligands”. Mini reviews in medicinal chemistry 5 (7): 641–9. DOI:10.2174/1389557054368844. PMID 16026310.

[1]

[2]

[3]

[4]

[5]